Biomimetic transport and rational drug delivery

Biochemical Pharmacology

Volumn 59, Issue 2, 2000, Pages 105-114

  Ranney, David F ^a,b  

^a Adv Radiological Sciences Division   (United States)

^b Access Pharmaceuticals Inc   (United States)

Author keywords

Active transport; Adenovirus; Dermatan sulfate; Radiopharmaceuticals in drug development; Targeted drug delivery; Vascular endothelium

Indexed keywords

DERMATAN; DRUG CARRIER; GLYCOSAMINOGLYCAN; OLIGOSACCHARIDE; POLYMER; RADIOISOTOPE;

ADENOVIRUS; DRUG DELIVERY SYSTEM; DRUG TARGETING; DRUG TRANSPORT; HUMAN; PRIORITY JOURNAL; REVIEW; VASCULAR ENDOTHELIUM;

EID: 0033991154     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00316-0     Document Type: Article

References (91)

1. Ranney D.F. Targeted modulation of acute inflammation. Science. 227:1985;182-184.
2. Ranney D.F. Drug targeting to the lungs. Biochem Pharmacol. 35:1986;1063-1069.
3. Ranney D.F. Magnetic microspheres for the targeted controlled release of drugs and diagnostic agents. Ann NY Acad Sci. 507:1987;104-119.
4. Ranney D.F. Magnetically controlled devices and biomodulation. Tyle P. Drug Delivery Devices Pharmaceutical and Biological Applications . 1988;325-368 Marcel Dekker, New York.
5. No payoff without delivery. Nat Biotechnol. 16:1998;115.
6. Jain R.K. Transport of molecules in the tumor interstitium A review . Cancer Res. 47:1987;3039-3051.
7. Bickerstaff M.C., Botto M., Hutchinson W.L., Herbert J., Tennent C.A., Bybee A., Mitchell D.A., Cook H.T., Butler P.J., Walport M.J., Pepys M.B. Serum amyloid P component controls chromatin degradation. Nat Med. 5:1998;694-697.
8. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R. Microvascular permeability and interstitial penetration of sterically stabilized (Stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
9. Wu J., Akaike T., Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58:1998;159-165.
10. Maeda H., Wu J., Tanaka S., Akaike T. Tumor vascular permeability and EPR effect for macromolecular therapeutics. Pitt C. Ninth International Symposium on Recent Advances in Drug Delivery Systems. 1999;114-117 Elsevier Scientific Publications, Shannon.
11. Konno T. Targeting chemotherapy for hepatoma Arterial administration of anticancer drugs dissolved in Lipiodol . Eur J Cancer. 28:1992;403-409.
12. Zlotecki R.A., Boucher Y., Lee I., Baxter L.T., Jain R.K. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res. 53:1993;2466-2468.
13. Jain R.K. Delivery of novel therapeutic agents in tumors Physiological barriers and strategies . J Natl Cancer Inst. 81:1989;570-576.
14. Dewanjee M.K., Ghafouripour A.K., Kapadvanjwala M., Dewanjee S., Serafini A.N., Lopez D.M., Sfakianakis G.N. Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. J Nucl Med. 35:1994;1054-1063.
15. Ranney D., Antich P., Cohen J., Erdman W., Kulkarni P., Giovanella B. Submillimeter monitoring of tumor-treatment response by contrast-enhanced magnetic resonance imaging (MRI) Implications for tumor access of antibodies, lymphokines and macromolecular drugs . Proc Am Assoc Cancer Res. 29:1988;495.
16. Langer K., Seidler C., Partsch H. Ultrastructural study of the dermal microvasculature in patients undergoing retrograde intravenous pressure infusions. Dermatology. 192:1996;103-109.
17. Sherman I.A., Dlugosz J.A., Barker F., Sadeghi F.M., Pang K.S. Dynamics of arterial and portal venous flow interactions in perfused rat liver An intravital microscopic study . Am J Physiol. 271:1996;G201-G210.
18. Watanabe T., Iijima Y., Abe K., Saito H., Naruke Y., Washio M. Retrograde brain perfusion beyond the venous values. Hemodynamic and intracellular pH mapping. J Thorac Cardiovasc Surg. 111:1996;36-44.
19. Young S.W., Qing F., Harriman A., Sessler J.L., Dow W.C., Mody T.D., Hemmi G., Hao Y., Miller R.A. Gadolinium(III) texaphyrin An MRI agent and radiosensitizer that localizes in tumors . Proc Natl Acad Sci USA. 93:1996;6610-6615.
20. Woodburn K.W., Fan Q., Kessel D., Miller R.A. Selective uptake of texaphyrins by atheromatous plaque. Proc SPIE. 2675:1996;172-178.
21. Kaufman E.N., Jain R.K. Effect of bivalent interaction upon apparent antibody affinity Experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays . Cancer Res. 52:1992;4157-4167.
22. Baxter L.T., Zhu H., Mackensen D.G., Jain R.K. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 54:1994;1517-1528.
23. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 12:1996;697-715.
24. Culty M., Miyake K., Kincade P.W., Sikorski E., Butcher E.C., Underhill C. The hyaluronate receptor is a member of the CD44 (H-CAM) family of cell surface glycoproteins. J Cell Biol. 111:1990;2765-2774.
25. DeGrendele H.C., Estess P., Picker L.J., Siegelman M.H. CD44 and its ligand hyaluronate mediate rolling under physiologic flow A novel lymphocyte-endothelial cell primary adhesion pathway . J Exp Med. 183:1996;1119-1130.
26. Catalina M.D., Estess P., Siegelman M.H. Selective requirements for leukocyte adhesion molecules in models of acute and chronic cutaneous inflammation Participation of E- and P- but not L-selectin . Blood. 93:1999;580-589.
27. Kiser P.F., Wilson G., Needham D. A synthetic mimic of the secretory granule for drug delivery. Nature. 394:1998;459-461.
28. Trail P.A., Willner D., Lasch S.J., Henderson A.J., Hofstead S., Casazza A.M., Firestone R.A., Hellstrom I., Hellstrom K.E. Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science. 261:1993;212-215.
29. Prochiantz A. Getting hydrophilic compounds into cells Lessons from homeopeptides . Curr Opin Neurobiol. 6:1996;629-643.
30. Derossi D., Calvet S., Trembleau A., Brunissen A., Chassaing G., Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem. 271:1996;18188-18193.
31. Joliot A., Trembleau A., Raposo G., Calvet S., Volovitch M., Prochiantz A. Association of engrailed homeoproteins with vesicles presenting caveolae-like properties. Development. 124:1997;1865-1875.
32. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
33. Hansen J.B., Olsen R., Webster P. Association of tissue factor pathway inhibitor with human umbilical vein endothelial cells. Blood. 90:1997;3567-3578.
34. Constantini V., De Monte P., Cazzato A.O., Stabile A.M., Deveglia R., Frezzato E., Paolucci M.C. Systemic thrombin generation in cancer patients is correlated with extrinsic pathway activation. Blood Coagul Fibrinolysis. 9:1998;79-84.
35. Ranney DF, Endothelial envelopment drug carriers. US Patent 5,108,759, issued April 28, 1992.
36. Ranney DF, In vivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans. US Patent 5,672,334, issued September 30, 1997.
37. Ranney DF, Complexes of dermatan sulfate and drugs, giving improved pharmacokinetics. European Patent EP 794 796 A1, published September 17, 1997.
38. Ranney DF, In vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles. US Patent 5,707,604, issued January 13, 1998.
39. x) oligosaccharides Ligands related to E-selectin (ELAM-1) binding . J Am Chem Soc. 114:1992;5449-5451.
40. Kieber-Emmons T, Otvos L and Glaszczyk-Thurin M, Peptide mimetics of carbohydrate structures developed by random peptide library and peptide array to inhibit metastasis. In: Anti-Cancer Proteins and Drugs: Structure, Function and Design (Ed. Lane DP), Abstr. P37. New York Academy of Sciences, November 6-9, New York, 1999.
41. Nguyen M., Eibler F.R., Defrees S. Novel synthetic analogues of sialyl Lewis X can inhibit angiogenesis in vitro and in vivo. Biochem Biophys Res Commun. 228:1996;716-723.
42. Zalipsky S., Mullah N., Harding J.A., Gittelman J., Guo L., DeFrees S.A. Poly(ethylene)glycol-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug Chem. 8:1997;111-118.
43. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
44. Maiti A., Maki G., Johnson P. TNF-α induction of CD44-mediated leukocyte adhesion by sulfation. Science. 282:1998;941-943.
45. Bischoff J. Cell adhesion and angiogenesis. J Clin Invest. 99:1997;373-376.
46. McEver R.P., Cummings R.D. The role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest. 100:1997;485-492.
47. Pasqualini R., Koivunen E., Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol. 15:1997;542-546.
48. Moser T.L., Stack M.S., Asplin I., Enghild J.J., Hojrup P., Everitt L., Hubchak S., Schnaper H.W., Pizzo S.V. Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci USA. 96:1999;2811-2816.
49. Reiseck K., Dorling A., Kemball-Cook G., McVey J.H., Jones M., Tuddenham E.G., Lechler R.I. Human tissue factor pathway inhibitor fused to CD4 binds both FXa and TF/FVIIa at the cell surface. Thromb Haemost. 78:1997;1488-1494.
50. Donati M.B. Cancer and thrombosis From phlegmasia alba dolens to transgenic mice . Thromb Haemost. 74:1995;278-281.
51. Sabharwal A.K., Bajaj S.P., Ameri A., Tricomi S.M., Hyers T.M., Dahms T.E., Taylor F.B. Jr, Bajaj M.S. Tissue factor pathway inhibitor and von Willebrand factor antigen levels in adult respiratory distress syndrome and in a primate model of sepsis. Am J Crit Care Med. 151:1995;758-767.
52. Zhang Y., Deng Y., Luther T., Muller M., Ziegler R., Waldherr R., Stern D.M., Nawroth P.P. Tissue factor controls the balance of angiogenic and antiangiogenic properties of tumor cells in mice. J Clin Invest. 94:1994;1320-1327.
53. Hu T., Bach R.R., Horton R., Konigsberg W.H., Todd M.B. Procoagulant activity in cancer cells is dependent on tissue factor expression. Oncol Res. 6:1994;321-327.
54. Lindahl A.K., Jacobsen P.B., Sandset P.M., Abildgaard U. Tissue factor pathway inhibitor with high anticoagulant activity is increased in post-heparin plasma and in plasma from cancer patients. Blood Coagul Fibrinolysis. 2:1991;713-721.
55. Drake S.L., Klein D.J., Mickelson D.J., Oegema T.R., Furcht L.T., McCarthy J.B. Cell surface phosphatidylinositol-anchored heparan sulfate proteoglycan initiates mouse melanoma cell adhesion to a fibronectin-derived, heparin-binding synthetic peptide. J Cell Biol. 117:1992;1331-1341.
56. Woods A., McCarthy J.B., Furcht L.T., Couchman J.R. A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation. Mol Biol Cell. 4:1993;605-613.
57. 1 integrin. J Cell Biol. 117:1992;449-459.
58. Maldonado B.A., Furcht L.T. Involvement of integrins with adhesion-promoting heparin-binding peptides of type IV collagen in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 36:1995;364-372.
59. Knutson J.R., Iida J., Fields G.B., McCarthy J.B. CD44/chondroitin sulfate proteoglycan and α2β1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell. 7:1996;383-396.
60. Ehnis T., Dieterich W., Bauer M., Lampe B., Schuppan D. A chondroitin/dermatan sulfate form of CD44 is a receptor for collagen XIV (undulin). Exp Cell Res. 15:1996;388-397.
61. O'Reilly M.S., Holmgren L., Chen C., Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med. 2:1996;689-692.
62. O'Reilly M.S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W.S., Flynn E., Birkhead J.R., Olsen B.R., Folkman J. Endostatin An endogenous inhibitor of angiogenesis and tumor growth . Cell. 88:1997;277-285.
63. Hellerqvist CG, Therapeutic agent and method of inhibiting vascularization of tumors. US Patent 5,010,062, issued April 23, 1991.
64. Wamil A.W., Wamil B.D., Hellerqvist C.G. CM101-mediated recovery of walking ability in adult mice paralyzed by spinal cord injury. Proc Natl Acad Sci USA. 95:1998;13188-13193.
65. TM: Selective site localization and accumulation, putative binding mechanism and enhanced pharmacokinetics and clearance. In: XII International Society of Human and Animal Mycology (Ed. Ellis D), Abstract P7.5. Blackwell Scientific Publications, Oxford, 1994.
66. TM. In: XII International Society of Human and Animal Mycology (Ed. Ellis D), Abstract PO2.58. Blackwell Scientific Publications, Oxford, 1994.
67. Mascellani G and Bianchini P, Dermatan sulphate possessing a thrombolytic activity, and pharmaceutical forms containing it. US Patent 5,547,944, issued August 20, 1996.
68. Esford L.E., Maiti A., Bader S.A., Tufaro F., Johnson P. Analysis of CD44 interactions with hyaluronan in murine L cell fibroblasts deficient in glycosaminoglycan synthesis A role for chondroitin sulfate . J Cell Sci. 111:1998;1021-1029.
69. Iida J., Meijne A.M., Knutson J.R., Furcht L.T., McCarthy J.B. Cell surface chondroitin sulfate proteoglycans in tumor cell adhesion, motility and invasion. Semin Cancer Biol. 7:1996;155-162.
70. Dadey E., Mason R., Ranney D., Fareed J., Constantinescu A., Chen H., Zadei J., Antich P. A new selective MRI contrast agent, ferrioxamine-dermatan sulfate Improved enhancement of AT-1 rat prostate carcinomas . J Magn Reson Imaging. 4:(P):1994;S11.
71. Ranney DF, Metal-ion chelates with acidic saccharides and glycosaminoglycans. European Patent EP 731 713 A1, published September 18, 1996.
72. Ranney DF, Methods and compositions for magnetic resonance imaging. European Patent WO 90/03190, published January 13, 1998.
73. Kulkarni P.V., Constantinescu A., Xiong R., Erdman W., Ranney D.F., Chen H., Eberhardt G.M., Parkey R.W., Antich P.P. Novel glycosaminoglycans (GLYCOS) for rapid tumor delivery of radionuclides by selective binding to neovascular endothelium Potential agents for tumor imaging and therapy . J Nucl Med. 36:(Suppl):1995;69P.
74. Kulkarni P.V., Antich P.P., Constantinescu A., Xiong R., Erdman W., Ranney D.F., Chen H., Zadei H.M., Eberhardt G.M., Parkey R.W. Structure and utilization of glycosaminoglycans (GLYCOS) as carriers in rapid selective delivery of radionuclides to tumors for application in tumor imaging and potential therapy. J Labelled Compd Radiopharm. 37:1995;808-810.
75. Ranney DF, In vivo agents comprising radioactive metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles. European Patent EP 726 781 A1, published August 21, 1996.
76. Kulkarni PV, Antich PP, Constantinescu A, Ranney DF, Fernando JL, Xiong R, Oz O and Parkey RW, Tumor imaging with novel radiogallium. In: Application of Accelerators in Research and Industry (Eds. Duggan JL and Morgan IL), Part Two, pp. 1341-1344. AIP Press, Woodbury, NY, 1996.
77. Ranney DF, Polychelating agents for image and spectral enhancement (and spectral shift). US Patent 5,336,762, issued August 9, 1994.
78. Ranney DF, Endothelial envelopment drug carriers. US Patent 4,925,678, issued May 15, 1990.
79. Kirn D.H., McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today. 2:1996;519-527.
80. Heise C., Sampson-Johannes A., Williams A., McCormick F., Von Hoff D.D., Kirn D.H. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 3:1997;639-645.
81. Duncan S.J., Gordon P.C.A., Gregory D.W., McPhie J.L., Postlethwaite R., White R., Willcox H.N.A. Infection of mouse liver by human adenovirus Type 3. J Gen Virol. 40:1978;45-61.
82. Hautala T., Grunst T., Fabrega A., Freimuth P., Welsh M.J. An interaction between penton base and αv integrins plays a minimal role in adenovirus-mediated gene transfer to hepatocytes in vitro and in vivo. Gene Ther. 5:1998;1259-1264.
83. Schneider G., Morral N., Parks R.J., Wu Y., Koopmans S.C., Langston C., Graham F.L., Beaudet A.L., Kochanek S. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity. Nat Genet. 18:1998;180-183.
84. Gu D.L., Gonzalez A.M., Printz M.A., Doukas J., Ying W., D'Andrea M., Hoganson D.K., Curiel D.T., Douglas J.T., Sosnowski B.A., Baird A., Aukerman S.L., Pierce G.F. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism Evidence for reduced toxicity and enhanced antitumor activity in mice . Cancer Res. 59:1999;2608-2614.
85. King I, Luo X, Lin S, Bermudes D and Sheng L-M, Salmonella typhimurium as a vector for protein delivery into tumors. In: Anti-Cancer Proteins and Drugs: Structure, Function and Design (Ed. Lane DP), Abstr. P47. New York Academy of Sciences, November 6-9, New York, 1999.
86. Ghandehari H., Crissman M., Crissman J., Ferrari F., Cappello J., Nagarsekar A. Stimuli-sensitive silk-elastin like block copolymers Synthesis by genetic engineering techniques . Pitt C. Ninth International Symposium on Recent Advances in Drug Delivery Systems. 1999;147-148 Elsevier Science, Shannon.
87. Nagarsekar A., Ghandehari H. Genetically engineered polymers for drug delivery. J Drug Target. 7:1999;11-32.
88. Cherry S.R., Shao Y., Silverman R.N., Chatziioannon A., Meadors K., Siegel S., Boutefnouchet A., Farquahr T., Young J., Jones W.F., Newport D., Moyers C., Andraeco M., Paulus M., Binkley D., Nutt R., Phelps M.E. MicroPET A high resolution PET scanner for imaging small animals . IEEE Trans Nucl Sci. 44:1997;1161-1166.
89. Eckleman WC and Gibson RE (Eds.), Proceedings: Use of imaging in drug R&D. J Clin Pharmacol 39 (Suppl): 1S-60S, 1999.
90. Kuo P., Sherwood J.K., Saltzman W.M. Topical antibody delivery systems produce sustained levels in mucosal tissue and blood. Nat Biotechnol. 16:1998;163-167.
91. Edelman E.R., Lovich M. Drug delivery transported to a new level. Nat Biotechnol. 16:1998;136-137.